Efficacy of Reboxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Boys With Intolerance to Methylphenidate: An Open-Label, 8-Week, Methylphenidate-Controlled Trial
Abstract
OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood. Principal treatment options for ADHD today include the psychostimulants, mainly methylphenidate (MPH). However, approximately 30% to 50% of children and adults with ADHD either do not respond to or do not tolerate treatment with stimulants. In this 8-week open-label, MPH-controlled, parallel group design study, we investigate the efficacy of reboxetine, a new selective norepinephrine reuptake inhibitor, in the treatment of boys with ADHD with a history of intolerance to MPH therapy. METHOD: Twenty-seven outpatient boys, aged 6 to 16 years, diagnosed with ADHD, participated in the study. Those with a history of intolerance to MPH therapy were assigned to treatment with reboxetine (2-8 mg/d), and the rest were assigned to treatment with MPH (10-20 mg/d) as the control group. The primary outcome measure for this study was the change in rating scores on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, ADHD Scale (DAS) that was assessed at baseline and at 8 weeks. RESULTS: At the end of 8 weeks, both reboxetine and MPH treatment regimens resulted in significant improvement in ADHD symptoms. The change in the reduction in the total DAS score and the DAS subscale scores between the reboxetine group and the MPH group was not statistically significant in any of the scores. CONCLUSIONS: Although preliminary, results of this study indicate that the use of reboxetine, a new selective norepinephrine reuptake inhibitor, in the treatment of ADHD could increase treatment options available for children who have shown intolerance or who are unresponsive to MPH.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Modafinil and reboxetine have both shown some promise in the treatment of ADHD.
“Modafinil [73] and reboxetine [74,75] have both shown some promise in the treatment of ADHD.”
From Advances in understanding and treating ADHD (2011) · cites this paper as [75]
Cites
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · see citing works
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677 · see citing works
Catecholamines in Attention-Deficit Hyperactivity Disorder: Current Perspectives
Pliszka, S. R., McCracken, J. T., & Maas, J. W. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199603000-00006 · Cited by 440 · see citing works
Treatment of Attention-Deficit–Hyperactivity Disorder
Elia, J., Ambrosini, P. J., & Rapoport, J. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401007 · Cited by 433 · see citing works
Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · see citing works
KRATOCHVIL, C. J., HEILIGENSTEIN, J. H., DITTMANN, R., SPENCER, T. J., BIEDERMAN, J., WERNICKE, J., NEWCORN, J. H., CASAT, C., MILTON, D., & MICHELSON, D. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00008 · Cited by 292 · see citing works
Dittmann, R., Fouche, D. S., Kratochvil, C. J., Heiligenstein, J. H., Spencer, T. J., & Biederman, J. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)80448-x · Cited by 223 · see citing works
Rating scales and checklists for child psychopharmacology.
Conners, C. K., & Barkley, R. A. (1985) · PubMed · Cited by 184 · see citing works
Versiani, M., Cassano, G. B., Perugi, G., Benedetti, A., Mastalli, L., Nardi, A. E., & Savino, M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0107 · Cited by 140 · see citing works
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
Wernicke, J. F., & Kratochvil, C. J. (2002) · PubMed · Cited by 129 · see citing works
Reid, W. H., Keller, S., Leatherman, M. E., & Mason, M. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0103 · Cited by 110 · see citing works
Спивак, Б., Vered, Y., Yoran‐Hegesh, R., Averbuch, E., Mester, R., Graf, E., & Weizman, A. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb07229.x · Cited by 99 · see citing works
Self-citationClinical psychopharmacology of AD/HD: Implications for animal models
Solanto, M. V. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00061-5 · Cited by 87 · see citing works
Novel treatments for attention-deficit/hyperactivity disorder in children.
Spencer, T. J., Biederman, J., Wilens, T. E., & Faraone, S. V. (2002) · PubMed · Cited by 83 · see citing works
Burrows, G. D., Maguire, K. P., & Norman, T. R. (1998) · PubMed · Cited by 77 · see citing works
Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Massana, J. (1998) · PubMed · Cited by 66 · see citing works
Спивак, Б., Vered, Y., Yoran‐Hegesh, R., Graff, E., Averbuch, E., Vinokurow, S., Weizman, A., & Mester, R. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.298 · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Advances in understanding and treating ADHD
Antshel, K. M., Hargrave, T. M., Simonescu, M., Kaul, P., Hendricks, K., & Faraone, S. V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-72 · Cited by 140 · see citing works
- Authors
- Cohen-Yavin, I., Yoran-Hegesh, R., Strous, R. D., Kotler, M., Weizman, A., & Spivak, B.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Cohen-Yavin, Iris
- Strous, Rael D.
- Kotler, Moshe
- Spivak, Baruch
- Venue
- Clinical Neuropharmacology
- Published
- 2009-07
- Volume
- 32
- Issue
- 4
- Pages
- 179-182
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2020855623
- Cited by
- 16
- References
- 17
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2018: 1 · 2016: 1 · 2015: 1 · 2014: 4 · 2013: 1 · 2012: 1
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- reboxetine, attention deficit hyperactivity disorder, norepinephrine reuptake inhibitors, boys, ADHD treatment efficacy
- MeSH terms
- Reboxetine, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Humans, Male, Methylphenidate, Morpholines, Patient Dropouts, Psychiatric Status Rating Scales, Psychometrics, Treatment Outcome, Adrenergic Uptake Inhibitors, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
